Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared a post on LinkedIn:
“The conversations at the American Society of Clinical Oncology (ASCO) Annual Meeting reinforced a critical fact: meaningful progress against colorectal cancer depends on bringing together the right expertise, resources, and commitment to innovation.
It was inspiring to see the Project Cure CRC Consortium of experts convene at ASCO to guide the Alliance’s work toward cures. The Colorectal Cancer Alliance’s Consortium got its first look at KLEOS – the Alliance’s adaptive clinical trial platform, which was the focus of a panel discussion featuring me, John Marshall, Christopher Lieu, Aparna Parikh and Meredith Buxton, CEO of the Global Coalition for Adaptive Research. Panelists shared KLEOS’s vast potential and urgent goal to bring new treatments to patients faster. The feedback we received will help drive our progress in the months ahead.
As a first-of-its-kind adaptive clinical trial platform in colorectal cancer, KLEOS represents an important step toward accelerating the development of new therapies and bringing promising treatment options to patients faster. This initiative has the potential to reshape how we evaluate and advance treatments for colorectal cancer.
Huge thank you to Scott Kopetz, Pashtoon Kasi, Emil Lou and Kristen Ciombor for their leadership as well.
The progress we need will not come from any one organization alone. It will come from collaboration across researchers, clinicians, advocates, industry leaders, and patients working toward a shared goal.
Thank you to everyone contributing their expertise and leadership to Project Cure CRC’s KLEOS. The momentum is real, and the opportunity to accelerate CRC innovation never been greater.”
More posts featuring Michael Sapienza.
